Consistent with prior findings, patients with MS taking B cell–depleting drugs exhibited lower anti–spike IgG responses and higher CD8 responses to spike protein peptides (14, 16, 17, 36, 45). This evidence concerns the gene CD8A and myeloid sarcoma.